PET Imaging Targeting Granzyme B Predicts Immunotherapy Efficacy in Diffuse Large B-cell Lymphoma

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06755775

Enrollment

150

Registered

2025-01-01

Start date

2024-07-23

Completion date

2029-07-23

Last updated

2025-01-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diffuse Large B-Cell Lymphoma

Keywords

PET/CT, Granzyme B, immunotherapy

Brief summary

This study aims to investigate the predictive value of PET imaging targeting granzyme B on the outcome of patients with diffuse large B lymphoma receiving immunotherapy.

Detailed description

The investigators will number all participants, create a medical record file, and record their basic information (gender, age) as well as contact information and medical history information. All participants will undergo 68Ga-grazytracer PET at baseline and after one course of immunotherapy (CAR-T, Glofitamab or iR2 ).

Interventions

None listed

Study design

Observational model

OTHER

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

1. Pathologic diagnosis of DLBCL 2. Patient's general condition is good and survival is expected to be greater than six months 3. Signed and dated informed consent form

Exclusion criteria

1. Combined with other malignant tumors 2. Patients with serious medical conditions who, in the opinion of the investigator, are not suitable for participation in this clinical study 3. Pregnant women and women at risk of pregnancy, breastfeeding women 4. poor compliant

Design outcomes

Primary

Measure	Time frame	Description
The value of PET imaging targeting granzyme B in predicting the efficacy of immunotherapy for diffuse large B-cell lymphoma	Baseline and 2 weeks after treatment	The value of PET imaging targeting granzyme B in predicting the efficacy of immunotherapy for diffuse large B-cell lymphoma
Standardized uptake value (SUV)	Baseline and 2 weeks after treatment	SUV of 68Ga-grazytracer uptake on PET/CT images for tumor lesions

Secondary

Measure	Time frame	Description
Progress free suivival	3 years	Progress free suivival
Overall survival	3 years	Overall survival

Countries

China

Contacts

Primary ContactXinyi Zhu

zxy16zz@163.com19121913585

Outcome results